Search PubMed⌕ Search

Biomedical subjects

V Braga

Publications and source records attributed to V Braga.

40 records · Page 3Linked to original sources
PubMed1976

[The action of the vaccinia virus upon placenta and fetus in revaccinated pregnants (author's transl)].

We studied 608 antivariolic revaccinated pregnants in spring 1972 at different ages of gestation. 60 presented spontaneous abortus; in 502 cases there has been performed therapeutical abortion, and 46 pregnants revaccinated after 2 1/2-3 months of gestation continued their pregnancy. Pregnancy and birth in revaccinated pregnants which did not abort, evolved without any difference against the witness-sample; the newborns presented in a higher percentage underweight. The absence of the vaccinia-virus and of Guarnieri-inclusions in the examined placentae and embryos as well as the moment of abortion, only after 20 days from the revaccination data, leads to the supposition that the placental lesions do not seem to be produced by the direct action of the virus by its replication, but probably by reactions of hypersensibility of the late type against the alergizin antigens of the antismallpox vaccine. The antivariolic revaccination of the sample of pregnants, showed that the vaccinia virus did not present a malformative action upon the embryo, but in change the abortive action was manifest in indirect proportion to the age of gestation.

Abortion, Spontaneous↗
PubMedDate not supplied

Short-term intravenous therapy with Neridronate in Paget's disease.

AIMS: To describe the effects of two consecutive intravenous infusions of aminohexane bisphosphonate (Neridronate) in patients with active Paget's disease of bone. METHODS: The study population included 83 patients, aged 41 to 85 years, randomized to 4 cumulative doses of Neridronate (25, 50, 100, 200 mg) given over 2 days, with a follow up of 180 days. The baseline serum alkaline phosphatase activity was at least 10% above the upper limit of the laboratory range. The response to treatment was assessed by changes in the serum total alkaline phosphatase (primary end point of the study), bone alkaline phosphatase and N-telopeptide urinary excretion. RESULTS: All Neridronate doses significantly suppressed the biochemical indices of disease activity. The nadir of total alkaline phosphatase levels ranged from -16 % to -57.5% of pretreatment values in the four groups, with a dose-response relationship that was apparent even between the two highest doses. The proportion of patients still maintaining a partial response (decreases in serum total alkaline phosphatase >25%) at the 6 month follow-up was also related to the dose: 98%, 67%, 57%, 21% in the patients given 200, 100, 50, 25 mg respectively. The proportion of responders in terms of bone alkaline phosphatase and N-telopeptide excretion changes was similar. Bone pain attributed to Paget's disease was significantly reduced. A typical acute phase reaction (fever and/or arthromyalgia) occurred in 16 out of 83 patients. CONCLUSIONS: We conclude that all of the Neridronate doses tested here were well tolerated and effective in decreasing, in a dose-related manner the bone turnover parameters of Paget's disease. The highest dose (200 mg) resulted in the normalization of the markers of disease activity in more than 60% of the patients.

Adult↗
PubMedDate not supplied

[Therapeutic strategies in osteoporosis: whom and when to treat].

Postmenopausal bone loss can be efficiently prevented by compounds which inhibit bone resorption, but they can not induce a sustained and relevant bone gain. The initial increase in bone volume observed within the first year of treatment is due to a transient uncoupling between bone resorption and formation: the first is suddenly blocked whereas bone formation decreases slowly within several months; bone is gained until the previously resorbed cavities are refilled. This net increase in bone mass is completely lost as soon as treatment is withdrawn. Since these antiresorptive agents can only be used in order to prevent bone loss, they should be given for several years. Thus, the choice of the drug is also conditioned by its cost and long-term compliance. Estrogen replacement is very convenient, from these points of view in most patients immediately after the menopause. Afterwards, parenteral calcitonin has been, up to now, the sole available alternative with convincing evidence of effectiveness, at least in the medium term. Its cost and the scarce compliance to injections have strongly limited its extensive use. There is increasing evidence that oral bisphosphonates are very effective and therefore they might represent, in the near future, an effective and convenient alternative to estrogen replacement therapy.

Aged↗